Search This Blog

Wednesday, March 6, 2019

BeiGene, Ambrx announce collaboration to develop biologics

Ambrx and BeiGene announced a global research and development collaboration. Ambrx has developed proprietary expanded genetic code technology platforms designed to allow the efficient incorporation of non-natural amino acids into proteins in both E. Coli and CHO cells. This technology enables site-specific modification of proteins to create potentially first- and/or best-in-class innovative protein drugs. The collaboration leverages Ambrx’s clinically validated drug discovery technology platforms with BeiGene’s expertise and resources to pursue the development and commercialization of next-generation biologics drugs. Under the terms of the agreement, Ambrx will receive an upfront payment of $10M to fund the initial discovery and research activities and additional upfront payments of up to $19M if BeiGene elects to initiate additional programs. Ambrx is eligible to receive potential development, regulatory, and sales-based milestone payments up to an aggregate of $446M for all programs, in addition to tiered royalties on future global sales. BeiGene will have worldwide rights to develop and commercialize any drug products resulting from the collaboration.
https://thefly.com/landingPageNews.php?id=2874977

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.